Navigation Links
Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
Date:10/14/2008

ROCKVILLE, Md., Oct. 14 /PRNewswire-FirstCall/ -- Neuralstem Inc., (Amex: CUR) today announced that it has licensed the rights to three inventions from Cleveland Clinic pertaining to Targeted Spinal Cord Therapeutics Delivery. All three inventions were developed by Dr. Nicholas Boulis MD, formerly of Cleveland Clinic, now at Emory University.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

"We are very pleased to have licensed-in these important delivery technology rights," said Neuralstem President & CEO, Richard Garr. "As we get ready to move into our expected human trial for ALS, we are focused on the optimal way to deliver our cell therapeutics to enhance the safety and efficacy of the treatments. Transplanting our cells directly into the spinal cord is a challenging but necessary part of trying to treat diseases of the spinal cord, not only in ALS, but in other spinal cord injuries and diseases." Garr went on to say, "The technology licensed today will help us to meet those goals."

Neuralstem will use this technology in its clinical trial for ALS (Amytrophic Lateral Sclerosis, or Lou Gehrig's disease). The company anticipates filing its IND (Investigational New Drug) application with the FDA for the ALS trial in the next few weeks, and hopes to start the trial early in 2009.

"Neuralstem is a second generation stem cell company," said Garr, "built not so much to do basic research and discovery, as to optimize our discovery of neural stem cells, and take them into the clinic and into patients. We believe that our technology answers many of the issues that have held the field back, and makes it possible to bu
'/>"/>

SOURCE Neuralstem Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neuralstem Announces Issuance of Core Technology Patent in Europe
2. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
3. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
4. Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
5. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
6. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
9. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Tianyin Pharmaceutical Co., Inc., (NYSE Amex: ... and markets patented biopharmaceutical, modernized traditional Chinese medicine, ... the senior management will host a conference call ... financial results at 8:30 a.m. E.T. on Tuesday, ...
... LEIPZIG, Germany, Feb. 8, 2011 Data from the ... the SUPERA® stent for peripheral arterial disease (PAD) of ... Leipzig Interventional Course (LINC).  The SUPERA stent is CE ...  In the United States the SUPERA stent is the ...
Cached Medicine Technology:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2011 Second Quarter Earnings Conference Call on Tuesday, February 15, 2011 at 8:30 a.m. E.T. 2One-Year European Registry Data Released for Popliteal Stenting With SUPERA® 2One-Year European Registry Data Released for Popliteal Stenting With SUPERA® 3
(Date:7/9/2014)... most common type of lung cancer, researchers have uncovered ... in forming tumors. The new knowledge may expand treatments ... changes already are available or are in clinical trials. ... from The Cancer Genome Atlas (TCGA), including researchers at ... Medical School and other institutions, studied tumors from 230 ...
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
(Date:7/9/2014)... and have a reputation for being highly toxic, but when ... being being found to offer potential health benefits in a ... dementia. A new compound (AP39), designed and made at the ... by targeting delivery of very small amounts of the substance ... Scientists in Exeter have already found that the compound protects ...
(Date:7/9/2014)... prescription labels handed out by pharmacists may be ... medication, according to new research by the University ... the Blind)., The study, published recently in the ... on prescription medications dispensed by pharmacies do not ... By simply following recommended guidelines for font size, ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... French . Robot-assisted surgery dramatically improves outcomes ... researchers at the Jewish General Hospital,s Lady Davis Institute ... post-operative complications and shorter hospital stays, robotic procedures also ... late 2010 in a series of studies in ...
... , WEDNESDAY, Jan. 12 (HealthDay News) -- People who have ... after receiving the results, whether they are positive or negative, ... or get screening tests that might modify that risk, despite ... in the Jan. 13 issue of the New England ...
... of Science (AAAS) has elevated four Dartmouth professors to the ... Dartmouth Medical School. Medical School faculty members Charles ... MD, join Dartmouth biologist C. Robertson McClung among the 504 ... eight other Dartmouth researchers to have earned the distinction. ...
... Jan. 12 (HealthDay News) -- Research in rats suggests that ... by persistent ringing or other noises in the ears. ... a result of hearing loss. In this study, U.S. ... variety of sound tones over an extended period of time. ...
... cancer with a relatively high degree of accuracy when applied ... cancer, according to a study in the January issue of ... was performed at the University of Washington and Seattle Cancer ... with 592 patients who were recently diagnosed with breast cancer ...
... Scientists are reporting a scientific basis for the long-standing belief ... other countries can prevent and treat cataracts, a clouding of ... of vision loss worldwide. Their study appears in Inorganic ... Wu, Fu-Yung Huang, Shih-Hsiung Wu and colleagues note that eye ...
Cached Medicine News:Health News:Robotic surgery of 'tremendous benefit' to patients, say JGH researchers 2Health News:Consumer Genetic Testing May Not Boost Users' Anxiety 2Health News:Consumer Genetic Testing May Not Boost Users' Anxiety 3Health News:Dartmouth Medical School faculty named fellows of the American Association for the Advancement of Science 2Health News:Animal Study Finds Nerve Stimulation May Thwart Tinnitus 2
GE's Signa Contour/i system uses the latest innovations from around the world to bring new standards in quality and value to MRI....
Intera 3.0T is the most compact high-field clinical whole-body MR system in the world, bringing 3.0T capabilities "out of the tunnel" and into the light of an open, patient-friendly design....
... The Akbarnia PDR Instruments ... surgeons negotiate in and around ... and reconstruction procedures. The instruments ... construction, a variety of angled ...
... Symphony Platelet Concentrate System is a ... of Platelet Concentrate (also referred to as ... Poor Plasma (PPP) from a small sample ... body's natural growth factors, which are found ...
Medicine Products: